Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MMSI
MMSI logo

MMSI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
68.270
Open
67.430
VWAP
67.39
Vol
689.88K
Mkt Cap
4.01B
Low
66.340
Amount
46.49M
EV/EBITDA(TTM)
13.80
Total Shares
59.43M
EV
4.34B
EV/OCF(TTM)
14.58
P/S(TTM)
2.72
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
Show More

Events Timeline

(ET)
2026-03-24
08:40:00
Medtronic Enters Distribution Agreement with Merit Medical
select
2026-03-16 (ET)
2026-03-16
09:30:00
Merit Medical Launches New Esophageal Stent
select
2026-02-24 (ET)
2026-02-24
16:20:00
Sees FY26 Revenue at $1.61B-$1.63B
select
2026-02-24
16:20:00
Merit Reports Q4 Revenue of $393.94M, Beating Expectations
select

News

NASDAQ.COM
7.5
03-24NASDAQ.COM
Medtronic Enters Exclusive Agreement with Merit for BVNA System
  • Exclusive Distribution Agreement: Medtronic has signed an exclusive agreement with Merit Medical Systems to launch the FDA-approved ViaVerte system, which is the first BVNA system with a physician-controlled steerable mechanism aimed at treating chronic vertebrogenic lower back pain, significantly enhancing treatment options for patients.
  • Product Innovation: The unique design of the ViaVerte system allows physicians to precisely target the basivertebral nerve, thereby improving treatment outcomes and further solidifying Medtronic's leadership in the pain intervention space while providing more effective solutions for chronic pain patients.
  • Strengthened Strategic Partnership: This agreement not only expands Medtronic's pain intervention product portfolio but also deepens the ongoing collaboration with Merit, which currently supplies Medtronic with Kyphon Xpander Inflation Syringes and Kyphon KyphoFlex unipedicular steerable balloon catheters used in balloon kyphoplasty procedures.
  • Market Impact: By introducing the ViaVerte system, Medtronic enhances its competitiveness in the chronic pain treatment market, which is expected to attract more patients to its innovative treatment options, thereby driving continued growth in the medical technology sector.
PRnewswire
7.5
03-24PRnewswire
Medtronic Enters Exclusive Agreement with Merit Medical
  • Innovative Treatment Solution: Medtronic has entered into an exclusive distribution agreement with Merit Medical to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation system, which is the first BVNA system with a physician-controlled steerable mechanism, significantly enhancing treatment options for chronic lower back pain patients.
  • Market Demand Response: According to the American Chronic Pain Association, approximately one in three Americans suffer from chronic pain, and the introduction of the ViaVerte™ system will provide these patients with a minimally invasive, same-day outpatient treatment option, addressing the growing market demand.
  • Deepening Strategic Partnership: This agreement not only continues the collaboration between Medtronic and Merit but also enhances Medtronic's leadership in the pain intervention field by incorporating Merit's proprietary technology, thereby diversifying its product portfolio.
  • Long-term Vision: Paolo Di Vincenzo, president of Medtronic's Neuromodulation division, stated that the addition of this new product will further expand their world-leading position in pain interventions, aiming to provide more effective treatment options for patients and physicians.
Newsfilter
7.5
03-24Newsfilter
Medtronic Enters Exclusive Agreement with Merit Medical
  • Innovative Treatment Solution: Medtronic has entered into a distribution agreement with Merit Medical to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation system, which is the first BVNA system with a physician-controlled steerable mechanism, significantly enhancing treatment options for chronic lower back pain patients.
  • Market Demand Response: According to the American Chronic Pain Association, approximately one in three Americans suffer from chronic pain, and the introduction of the ViaVerte™ system will provide these patients with a minimally invasive, same-day outpatient treatment option, addressing the growing market demand.
  • Deepening Strategic Partnership: This agreement not only continues the collaboration between Medtronic and Merit but also integrates Merit's proprietary technology into Medtronic's pain intervention product portfolio, further solidifying its leadership position in the healthcare technology sector.
  • Business Expansion Potential: Medtronic's pain therapy portfolio includes spinal cord stimulation and vertebral augmentation, and the addition of ViaVerte™ will directly meet the demand for new therapies, driving the company's continued growth in the chronic pain treatment market.
moomoo
7.5
03-24moomoo
Medtronic and Merit Medical Systems Partner to Launch FDA-Cleared ViaVerte™ System for Chronic Lower Back Pain Treatment
  • Agreement Announcement: Medtronic has entered into an agreement to offer a new treatment for chronic vertebrogenic lower back pain.

  • FDA Clearance: The treatment involves the use of the FDA-cleared VERTEX™ system, which is designed for ablation of nerve tissue.

seekingalpha
2.0
03-17seekingalpha
U.S. Healthcare Stocks Plunge Amid Geopolitical Tensions
  • Oversold Healthcare Stocks: The ongoing geopolitical tensions have led to significant selling pressure in healthcare stocks, with Merit Medical Systems (MMSI) and Option Care Health (OPCH) showing RSIs of 29.03 and 28.79 respectively, indicating strong sell sentiment in the market.
  • Potential for Short-term Rebound: While the current oversold conditions typically signal heavy selling, these healthcare stocks could be well-positioned for a quick bounce-back if geopolitical news improves, particularly for companies like Crinetics Pharmaceuticals (CRNX) and Prestige Consumer Healthcare (PBH).
  • Increased Market Volatility: As the conflict enters its 16th day, overall market volatility has intensified, pushing several key sectors into technically oversold territory, with 15-day performance showing widespread declines, including Bio-Techne Corporation (TECH) down 13.81% and iRhythm Holdings (IRTC) down 15.51%.
  • Investor Focus: Amid the turmoil in the Middle East, investor attention on healthcare stocks has risen, especially for companies like Eli Lilly and Novo Nordisk, with the market eagerly anticipating their future performance amidst the current challenges.
seekingalpha
9.5
02-25seekingalpha
Merit Medical Systems Reports Strong Q4 2025 Earnings with Record Free Cash Flow
  • Significant Revenue Growth: Merit Medical Systems reported total revenue of $393.9 million in Q4 2025, reflecting an 11% year-over-year increase, with U.S. sales up 12% and international sales up 6%, demonstrating strong performance across major markets and reinforcing its competitive position.
  • Record Free Cash Flow: The company achieved a record free cash flow of $74 million in Q4, contributing to nearly $216 million for the full year 2025, indicating ongoing improvements in cash management and profitability that will support future investments and shareholder returns.
  • Margin Expansion: The non-GAAP operating margin increased to 21% in Q4, up 138 basis points year-over-year, with a gross margin of 54.5%, marking the highest quarterly gross margin in the company's history, reflecting successful cost control and product mix optimization.
  • Cautious 2026 Outlook: The company projects total GAAP net revenue growth of 6% to 8% for 2026, factoring in a 140 basis point headwind to revenue growth from the divestiture of the DualCap product line, as management remains vigilant about external challenges while maintaining confidence in growth prospects.
Wall Street analysts forecast MMSI stock price to rise
8 Analyst Rating
Wall Street analysts forecast MMSI stock price to rise
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
90.00
Averages
104.63
High
122.00
Current: 0.000
sliders
Low
90.00
Averages
104.63
High
122.00
Wells Fargo
Overweight -> Equal Weight
downgrade
AI Analysis
2026-02-26
Reason
Wells Fargo
Price Target
AI Analysis
2026-02-26
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded Merit Medical to Equal Weight from Overweight.
Wells Fargo
Overweight -> Equal Weight
downgrade
$95 -> $78
2026-02-26
Reason
Wells Fargo
Price Target
$95 -> $78
2026-02-26
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded Merit Medical to Equal Weight from Overweight with a price target of $78, down from $95. The firm cites uncertainty regarding the company's fiscal 2026 guidance for the downgrade. Wells sees limited upside to the guidance if Merit's Q1 headwinds persist. There is no clear catalyst to support a reacceleration of Merit's growth, the analyst tells investors in a research note. Wells cites guidance uncertainty and a lack of catalysts for the downgrade.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MMSI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Merit Medical Systems Inc (MMSI.O) is 22.16, compared to its 5-year average forward P/E of 25.74. For a more detailed relative valuation and DCF analysis to assess Merit Medical Systems Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
25.74
Current PE
22.16
Overvalued PE
29.19
Undervalued PE
22.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
17.68
Current EV/EBITDA
15.60
Overvalued EV/EBITDA
19.48
Undervalued EV/EBITDA
15.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.39
Current PS
3.25
Overvalued PS
3.78
Undervalued PS
3.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding MMSI

O
Oberweis Asset Management, Inc.
Holding
MMSI
+23.87%
3M Return
F
Fuller & Thaler Asset Management, Inc.
Holding
MMSI
+12.73%
3M Return
W
Westwood Management Corp.
Holding
MMSI
+9.47%
3M Return
C
Conestoga Capital Advisors, LLC
Holding
MMSI
-3.07%
3M Return
A
Alaska Permanent Fund
Holding
MMSI
-3.52%
3M Return
A
AMI Asset Management Corp
Holding
MMSI
-5.88%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Merit Medical Systems Inc (MMSI) stock price today?

The current price of MMSI is 67.55 USD — it has decreased -0.85

What is Merit Medical Systems Inc (MMSI)'s business?

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

What is the price predicton of MMSI Stock?

Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is104.63 USD with a low forecast of 90.00 USD and a high forecast of 122.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Merit Medical Systems Inc (MMSI)'s revenue for the last quarter?

Merit Medical Systems Inc revenue for the last quarter amounts to 393.94M USD, increased 10.92

What is Merit Medical Systems Inc (MMSI)'s earnings per share (EPS) for the last quarter?

Merit Medical Systems Inc. EPS for the last quarter amounts to 0.63 USD, increased 36.96

How many employees does Merit Medical Systems Inc (MMSI). have?

Merit Medical Systems Inc (MMSI) has 7500 emplpoyees as of March 25 2026.

What is Merit Medical Systems Inc (MMSI) market cap?

Today MMSI has the market capitalization of 4.01B USD.